Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
6.39
-0.13 (-1.99%)
At close: Nov 13, 2026, 4:00 PM EST
6.51
+0.12 (1.88%)
After-hours: Nov 13, 2026, 7:53 PM EST
Immatics Employees
Immatics had 704 employees as of June 30, 2026. The number of employees increased by 58 or 8.98% compared to the same quarter last year. That makes Immatics the 17,438th largest employer in the world and 2,409th in the United States.
Employees
704
Change (1Y)
58
Growth (1Y)
8.98%
Revenue / Employee
$70,071
Profits / Employee
-$374,270
Market Cap
873.45M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 704 | 58 | 8.98% | 704 | 0 |
| Mar 31, 2026 | 678 | 32 | 4.95% | 678 | 0 |
| Dec 31, 2025 | 711 | 29 | 4.25% | 589 | 122 |
| Sep 30, 2025 | 645 | 73 | 12.76% | 645 | 0 |
| Mar 31, 2025 | 646 | 111 | 20.75% | 646 | 0 |
| Dec 31, 2024 | 682 | 147 | 27.48% | 554 | 128 |
| Sep 30, 2024 | 572 | 139 | 32.10% | 572 | 0 |
| Jun 30, 2024 | 542 | 140 | 34.83% | 542 | 0 |
| Dec 31, 2023 | 535 | 93 | 21.04% | 432 | 103 |
| Sep 30, 2023 | 433 | 45 | 11.60% | 433 | 0 |
| Mar 31, 2023 | 402 | 29 | 7.77% | 402 | 0 |
| Dec 31, 2022 | 442 | 61 | 16.01% | 358 | 84 |
| Jun 30, 2022 | 388 | 57 | 17.22% | 388 | 0 |
| Mar 31, 2022 | 373 | 90 | 31.80% | 373 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 407 |
| MeiraGTx Holdings | 386 |
| Syndax Pharmaceuticals | 298 |
| Rigel Pharmaceuticals | 174 |
| Odyssey Therapeutics | 100 |
| Inventiva | 87 |
| Corvus Pharmaceuticals | 37 |
IMTX News
- 2 days ago - Immatics price target lowered to $14 from $17 at BofA - TheFly
- 5 days ago - Immatics reports Q3 EPS (EUR 0.50) vs. (EUR 0.42) last year - TheFly
- 5 days ago - Immatics Announces Third Quarter 2026 Financial Results and Business Update - GlobeNewsWire
- 17 days ago - Immatics price target lowered to $21 from $25 at Mizuho - TheFly
- 21 days ago - Immatics announces updated trial data from Phase 1b study of IMA402 - TheFly
- 22 days ago - Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting - GlobeNewsWire
- 4 weeks ago - Immatics initiated with a Buy at Stifel - TheFly
- 2 months ago - Immatics price target lowered to $17 from $18 at Jefferies - TheFly